BioCorRx Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $797.2K | $7.7K | $89.2K | $213.8K | $48.3K | $122.6K | $240.3K | $376.7K |
| Cost of Revenue | — | $1.7K | $36.0K | $15.3K | $5.9K | $95.9K | $81.7K | $171.0K |
| Gross Profit | — | $6.0K | $53.2K | $198.6K | $42.4K | $26.7K | $158.6K | $205.7K |
| Gross Margin | — | 78.3% | 59.6% | 92.9% | 87.8% | 21.8% | 66.0% | 54.6% |
| Operating Expenses | ||||||||
| Research & Development | $1.8M | $1.5M | $891.1K | $1.5M | $1.6M | $4.3M | $1.1M | $151.8K |
| SG&A Expense | $3.8M | $3.6M | $2.9M | $3.4M | $3.7M | $3.2M | $4.6M | $4.4M |
| Operating Income | $-4.8M | $-5.1M | $-3.8M | $-4.7M | $-5.5M | $-7.5M | $-5.6M | $-4.6M |
| Operating Margin | -606.0% | -66,829.8% | -4,248.3% | -2,197.0% | -11,414.7% | -6,109.9% | -2,314.7% | -1,228.2% |
| Interest Expense | $223.9K | $776.8K | $194.0K | $151.0K | $19.4K | $511.0K | $1.6M | $-2.0M |
| Pretax Income | $-3.5M | $-5.2M | $-3.8M | $-4.4M | $-5.2M | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net Income | $-3.4M | $-5.1M | $-3.8M | $-4.4M | $-5.2M | $-3.5M | $-6.0M | $-6.6M |
| Net Margin | -431.5% | -66,616.1% | -4,228.9% | -2,046.8% | -10,794.3% | -2,859.6% | -2,517.4% | -1,748.1% |
| EPS (Basic) | — | — | — | — | $-0.20 | $-0.16 | $-0.43 | $-0.65 |
| EPS (Diluted) | $-0.19 | $-0.49 | — | — | $-0.20 | $-0.16 | $-0.43 | $-0.65 |
| Shares Outstanding (Basic) | — | — | — | — | — | — | — | — |
| Shares Outstanding (Diluted) | 18.5M | 10.5M | 10.8M | 5.8M | 4.2M | 4.6M | 4.5M | 9.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |